Phillip Rozeman, MD
Cardiovascular Disease · Shreveport, LANPI 1699740035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.
Across 220 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$572
- Novartis$376
- Abiomed$324
- Medtronic$313
- Merck$282
- Terumo Medical Corporation$276
- plus $2K from 29 others
Across 1 payment — averaging $11,327 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
What the payments were for
- Travel & lodging$1664%
- Food & beverage$3,90294%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $572 |
| Novartis | 27 | $376 |
| Abiomed | 5 | $324 |
| Medtronic(2 entities) | 11 | $313 |
| Merck | 17 | $282 |
| Terumo Medical Corporation | 3 | $276 |
| Inari Medical, Inc. | 14 | $215 |
| Boston Scientific | 14 | $176 |
| E.r. Squibb & Sons, L.L.C. | 10 | $175 |
| Amgen | 9 | $156 |
| Sanofi-aventis U.S. LLC | 10 | $155 |
| Irhythm Technologies, Inc. | 6 | $123 |
| Lexicon Pharmaceuticals, Inc. | 5 | $117 |
| Pfizer | 7 | $104 |
| Bayer | 5 | $101 |
| Novo Nordisk | 4 | $72 |
| Boehringer Ingelheim | 4 | $67 |
| Kestra Medical Technology Services, Inc. | 3 | $65 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Stryker | 2 | $45 |
| Ionis Pharmaceuticals, Inc. | 2 | $43 |
| Philips North America LLC | 3 | $43 |
| Johnson & Johnson | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Preventice Services, LLC | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 2 | $25 |
| Itamar Medical Inc | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| ZOLL Circulation Inc | 1 | $18 |
| Recor Medical Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| GE HealthCare | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$249
- Optitorque$166
- Heartrail$166
- TR Band$166
- Glidesheath$166
- COBALT DR MRI SURESCAN$101
How this compares
$4,157 in reported general payments places this provider in the 55th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 214 | $214,329 |
| EliquisApixaban | 204 | $183,540 |
| BrilintaTicagrelor | 39 | $28,371 |
| JardianceEmpagliflozin | 35 | $26,943 |
| XareltoRivaroxaban | 22 | $20,912 |
| FarxigaDapagliflozin Propanediol | 23 | $19,956 |
| Repatha SureclickEvolocumab | 28 | $18,891 |
| Metoprolol Succinate | 509 | $6,321 |
| Ranolazine ErRanolazine | 51 | $4,722 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 368 | $3,476 |
| ClopidogrelClopidogrel Bisulfate | 217 | $2,154 |
| Atorvastatin Calcium | 239 | $1,926 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,762 |
| Losartan Potassium | 206 | $1,603 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 106 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $376 | $214,329214 claims |
| PfizerEliquis | $104 | $183,540204 claims |
| Boehringer IngelheimJardiance | $67 | $26,94335 claims |
| Johnson & JohnsonXarelto | $40 | $20,91222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Tina FirouzbakhtShreveport$28K
- Wenwu ZhangShreveport$21K
- William EavesShreveport$15K
- Jagan BeedupalliShreveport$13K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.